{
    "clinical_study": {
        "@rank": "41921", 
        "acronym": "BeyPro1", 
        "arm_group": {
            "arm_group_label": "Fotemustine  + Vemurafenib", 
            "arm_group_type": "Experimental", 
            "description": "Fotemustine 100 mg/m2 q21 + Vemurafenib gelatin capsules supplied as 240-mg strengths. Vemurafenib will be administered continuous oral dosing at 960 mg twice daily or dose administered at time of disease progression with Vemurafenib previous treatment."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the activity of Vemurafenib in combination with\n      Fotemustine in Patients with unresectable Stage IV melanoma harboring V600 BRAF mutation who\n      recurred while in treatment with Vemurafenib. In addition the feasibility and safety profile\n      of prolonging treatment of this drugs combination will be assessed."
        }, 
        "brief_title": "Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Melanoma Stage IV", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "Patients are treated with Fotemustine 100 mg/m2 q21 + Vemurafenib. Vemurafenib will be\n      administered continuous oral dosing at 960 mg twice daily or dose administered at time of\n      disease progression with Vemurafenib previous treatment (720 or 480 mg).Treatment will be\n      continued until progression or unacceptable toxicity. The Progression-free survival will be\n      assessed as primary endpoint, other outcomes(i.e., incidence of grade III-IV toxicity,\n      Disease Control Rate, and Overall Survival) will be considered secondary endpoints."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed melanoma harboring the V600 mutation\n\n          -  Unresectable Stage IV melanoma\n\n          -  At least 18 y of age\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of <2\n\n          -  In progression during  treatment with Vemurafenib\n\n          -  At least 2 weeks  since  the last radiotherapy treatment\n\n          -  Life expectancy >12 weeks\n\n          -  Clinical laboratory values at screening defined as follow: lactate dehydrogenase\n             (LDH) < 2.0 x upper limit of normal (ULN), Hemoglobin >9 g/dL, Absolute neutrophil\n             count 1500/mm3, Platelet count >100,000/mm3, Creatinine <1.5 mg/dL  (NOTE: If\n             creatinine is >1.5 mg/dL, subject is eligible if creatinine clearance > 60 mL/min\n             using the Cockgroft-Gault equation), Total bilirubin <1.5 x ULN, Aspartate\n             aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase\n             (ALP) <2.5 x ULN\n\n          -  Negative serum pregnancy test within 7 days prior to commencement of dosing in\n             premenopausal women. Women of non-childbearing potential may be included if they are\n             either surgically sterile or have been postmenopausal for \u2265 1 year\n\n          -  Fertile men and women must use an effective method of contraception\n\n          -  Absence of any psychological, familial, sociological or geographical condition\n             potentially hampering compliance with the study protocol and follow-up schedule\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Female subjects who are pregnant or nursing\n\n          -  Female subjects of childbearing potential or males not using or not willing to use\n             two forms of effective contraception\n\n          -  Any of the following within the 6 months prior to randomization: myocardial\n             infarction, severe/unstable angina, symptomatic congestive heart failure,\n             cerebrovascular accident or transient ischemic attack,  pulmonary embolism,\n             hypertension not adequately controlled by current medications\n\n          -  Concurrent administration of any anti-cancer therapies (e.g. chemotherapy, other\n             targeted therapy, experimental drug, etc) other than those administered in this study\n\n          -  Known hypersensitivity to Vemurafenib or another BRAF inhibitor\n\n          -  History of congenital long QT syndrome, history or presence of clinically significant\n             ventricular or atrial dysrhythmias \u2265 Grade 2 (NCI Common Toxicity Criteria for\n             Adverse Effects (CTCAE) Version 4.0\n\n          -  Corrected QT (QTc) interval \u2265 500 msec at baseline\n\n          -  Uncontrolled medical illness (such as infection requiring treatment with intravenous\n             (IV) antibiotics)\n\n          -  Has had surgery within 2 weeks (1 week for minor surgery, eg, procedures requiring\n             only local anesthetics) prior to the first dose of study medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983124", 
            "org_study_id": "2012-004172-18"
        }, 
        "intervention": {
            "arm_group_label": "Fotemustine  + Vemurafenib", 
            "description": "Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.\nVemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity.", 
            "intervention_name": "Fotemustine  + Vemurafenib", 
            "intervention_type": "Drug", 
            "other_name": [
                "Fotemustine", 
                "Zelboraf"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Fotemustine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Advanced Melanoma", 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "zip": "16132"
                    }, 
                    "name": "Paola Queirolo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "zip": "80131"
                    }, 
                    "name": "Istituto Nazionale per lo Studio e la Cura dei Tumori \"G.Pascale\""
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Single-arm Study for the Treatment After Recurrence of Advanced Melanoma Patients Harboring the V600BRAF Mutation and Pretreated With Vemurafenib, With the Association of Vemurafenib Plus Fotemustine.", 
        "overall_official": {
            "affiliation": "IRCCS AOU San Martino IST", 
            "last_name": "Paola Queirolo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess activity of vemurafenib in combination with fotemustine, in patients harboring the V600BRAF mutation and recurred while on treatment with Vemurafenib.", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983124"
        }, 
        "responsible_party": {
            "investigator_affiliation": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", 
            "investigator_full_name": "Paola Queirolo", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of Grade 3-4 toxicities (any type)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Rate, duration of response and proportion of patients with duration of response lasting > 24 weeks", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Disease control rate;", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Time to progression of brain metastases (BM), Including  incidence of BM in pts free from BM at the time of enrolment", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Overall survival (OS).", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", 
        "sponsors": {
            "collaborator": {
                "agency": "Istituto Nazionale per lo Studio e la Cura dei Tumori", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Paola Queirolo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}